Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL) Shorts Strengthened By 9.18%

June 29, 2018 - By Joseph Taylor

It was reported an increase on Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL)’s short interest with 9.18%. FINRA announced short interest of ZEAL’s total 254,500 shares. That’s 9.18% up from 233,100 shares. With Average volume 6,100, ZEAL’s former position will take 42 days to recover. 1.1% is Zealand Pharma A/S – American Depositary Shares float short.

The stock increased 0.54% or $0.07 during the last trading session, hitting $13.Currently Zealand Pharma A/S is after 0.00% change in last June 29, 2017. ZEAL has 3,000 shares volume. ZEAL underperformed by 12.57% the S&P500.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics medicines in Denmark.The firm is worth $424.62 million. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases.Currently it has negative earnings. The firm markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

Another two news for Zealand Pharma A/S (NASDAQ:ZEAL) were recently released by: Streetinsider.com on June 08, 2018 with title “Zealand Pharma (ZEAL) Phase 3 Trial of Dasiglucagon Met Primary and Secondary Objectives”. The other Seekingalpha.com‘s article was titled “Your Daily Pharma Scoop: Zealand Dips, Eloxx Surges, Venetoclax Approved” and released on June 11, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.